COLOPLAST UN.ADR 1/10 DK1 Logo
US19624Y2000
A2P4CC
CLPBY

COLOPLAST UN.ADR 1/10 DK1

Loading quotes...

Forecast

The analysts' average price target is €6.71 (-0.59%). The median is €6.71 (-0.59%).

Buy
  3
Hold
  3
Sell
  2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

Historical dividends Dividends

All dividend metrics All metrics
In 2026, COLOPLAST UN.ADR 1/10 DK1 has already paid €0.0668 in dividends. The last payout was in June.

Financials

In the last quarter, COLOPLAST UN.ADR 1/10 DK1 had revenue of €991.3m and net profit of €157.62m
(EUR) September 2026
YoY
Revenue 991.3m 38.57%
Gross profit 649.35m 2.13%
Net profit 157.62m 34.92%
EBITDA 291.18m 0.16%

Fundamentals

Metric Value
Market capitalization
€15.35bn
Number of shares
2.25bn
52-week high/low
€8.45 - €5.13
Dividend yield
4.56%
Dividends TTM
€0.31
Next dividend
€0.13
Beta
0.53
P/E ratio
37.24
PEG ratio
-2.41
P/B ratio
8.01
P/S ratio
3.96

Company profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

Name
COLOPLAST UN.ADR 1/10 DK1
CEO
Gavin Wood
Headquarters Humlebæk, ze
Denmark
Website
IPO
13/01/2014
Employees 17,524

Ticker symbols

Exchange Symbol
Pnk
CLPBY
Frankfurt
CBH.F
DĂĽsseldorf
CBH.DU
MĂĽnchen
CBH.MU
🍪

Parqet  uses cookies. Learn more